207 related articles for article (PubMed ID: 20431519)
1. Everolimus and pazopanib: two new drugs for renal cell cancer.
Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
[No Abstract] [Full Text] [Related]
2. Pazopanib in renal cell carcinoma.
Sternberg CN
Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
[No Abstract] [Full Text] [Related]
3. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib.
Bukowski RM; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
[TBL] [Abstract][Full Text] [Related]
6. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
Becze E
ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
[No Abstract] [Full Text] [Related]
7. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
[TBL] [Abstract][Full Text] [Related]
8. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
Grgic T; Mis L; Hammond JM
Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib: therapeutic developments.
Limvorasak S; Posadas EM
Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
[TBL] [Abstract][Full Text] [Related]
12. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
Matrana MR; Ng C; Rao P; Lim ZD; Tannir NM
Clin Genitourin Cancer; 2011 Dec; 9(2):137-9. PubMed ID: 21831725
[No Abstract] [Full Text] [Related]
13. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
15. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
[TBL] [Abstract][Full Text] [Related]
16. New mTOR inhibitor for renal cell cancer.
Wilkes GM
Oncology (Williston Park); 2009 Jul; 23(8 Suppl):54-6. PubMed ID: 19860046
[No Abstract] [Full Text] [Related]
17. [Pharmacological sheet: pazopanib (Votrient), oral administration].
J Pharm Belg; 2011 Sep; (3):95-6. PubMed ID: 21995103
[No Abstract] [Full Text] [Related]
18. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
[TBL] [Abstract][Full Text] [Related]
19. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
Bourdeanu L; Twardowski P; Pal SK
Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
[TBL] [Abstract][Full Text] [Related]
20. Lingual angioedema associated with everolimus.
Mackenzie M; Wood LA
Acta Oncol; 2010; 49(1):107-9. PubMed ID: 20100146
[No Abstract] [Full Text] [Related]
[Next] [New Search]
